{
    "clinical_study": {
        "@rank": "67278", 
        "arm_group": {
            "arm_group_label": "ALT-803", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation\n      study of ALT-803 in patients with relapsed or refractory multiple myeloma."
        }, 
        "brief_title": "A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma", 
        "completion_date": {
            "#text": "July 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsed or Refractory Multiple Myeloma", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the safety, determine the Maximum Tolerated Dose\n      (MTD) or the Minimum Efficacious Dose (MED) and characterize the immunogenicity and\n      pharmacokinetic profile of ALT-803 in treated patients. The effect of ALT-803 on the\n      peripheral absolute lymphocyte counts and white blood cell counts, the number and phenotype\n      of peripheral blood T (total and subsets) and NK cells will be evaluated.  The anti-tumor\n      responses of ALT-803 will also be assessed in this trial."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "ENTRY CRITERIA:\n\n        DISEASE CHARACTERISTICS:\n\n          -  Confirmed diagnosis of relapsed/refractory multiple myeloma after treatment with at\n             least two different previous regimens.\n\n               -  Refractory disease is defined as progressive disease while on therapy or\n                  progression within 60 days of therapy.\n\n               -  Progressive disease is defined by a 25% increase from the lowest response value\n                  in specified tests.\n\n          -  Measurable disease as defined by at least one of the following:\n\n               -  Serum M-protein \u2265 1g/dL (for IgG, IgM) or 0.5 g/dL (for IgA)\n\n               -  Urine M-protein \u2265 200mg/24hours\n\n               -  Serum free light chains \u2265 10 mg/dL and abnormal kappa/lambda ratio\n\n        PRIOR/CONCURRENT THERAPY:\n\n          -  No anti-myeloma treatments within 28 days before the start of study treatment.\n\n          -  Must have recovered from side effects of prior treatments.\n\n        PATIENT CHARACTERISTICS:\n\n        Performance Status\n\n        \u2022 ECOG 0, 1, or 2\n\n        Bone Marrow Reserve\n\n          -  Absolute neutrophil count (AGC/ANC) \u2265 1000/uL\n\n          -  Platelets \u2265 30,000/uL\n\n          -  Hemoglobin \u2265 8g/dL\n\n          -  Absolute lymphocytes \u2265 800/uL\n\n          -  Leukocytes \u2265 3,000/uL\n\n        Renal Function\n\n        \u2022 Glomerular Filtration Rate (GFR) > 45mL/min/1.73m^2\n\n        Hepatic Function\n\n          -  Total bilirubin \u2264 2.0 X ULN\n\n          -  AST, ALT, ALP \u2264 3.0 X ULN, or \u2264 5.0 X ULN (if liver metastases exist)\n\n          -  No positive Hep C serology or active Hep B infection\n\n        Cardiovascular\n\n          -  No congestive heart failure < 6 months\n\n          -  No unstable angina pectoris < 6 months\n\n          -  No myocardial infarction < 6 months\n\n          -  No history of ventricular arrhythmias\n\n          -  No history of supraventricular arrhythmias\n\n          -  No NYHA Class > II CHF\n\n          -  No marked baseline prolongation of QT/QTc interval\n\n        Pulmonary\n\n        \u2022 Normal clinical assessment of pulmonary function\n\n        Other\n\n          -  Negative serum pregnancy test if female and of childbearing potential\n\n          -  Women who are not pregnant or nursing\n\n          -  Subjects, both females and males, with reproductive potential must agree to use\n             effective contraceptive measures for the duration of the study\n\n          -  No known autoimmune disease other than corrected hypothyroidism\n\n          -  No known prior organ allograft or allogeneic transplantation\n\n          -  Not HIV positive\n\n          -  No history or evidence of uncontrollable CNS disease\n\n          -  No psychiatric illness/social situation\n\n          -  No other illness that in the opinion of the investigator would exclude the subject\n             from participating in the study\n\n          -  Must provide informed consent and HIPPA authorization and agree to comply with all\n             protocol-specified procedures and follow-up evaluations\n\n          -  No active systemic infection requiring parenteral antibiotic therapy\n\n          -  No ongoing chronic systemic steroid therapy or regular inhaled cortocosteroid use"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099539", 
            "org_study_id": "CA-ALT-803-02-13"
        }, 
        "intervention": {
            "arm_group_label": "ALT-803", 
            "description": "Intravenous infusion; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles", 
            "intervention_name": "ALT-803", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "absolute lymphocyte count", 
            "antitumor", 
            "cancer", 
            "immunotherapy", 
            "immunochemotherapy", 
            "interleukin-15", 
            "multiple myeloma", 
            "NK cell", 
            "refractory", 
            "relapsed", 
            "T cell", 
            "white blood cell count"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota Masonic Cancer Center"
            }, 
            "investigator": {
                "last_name": "Jeffrey Miller, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase Ib/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Altor Bioscience Corporation", 
            "last_name": "Hing C Wong, PhD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "For phase Ib & II\nNumber and severity of treatment related AEs that occur or worsen after the first dose of study treatment.", 
                "measure": "Safety Profile", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }, 
            {
                "description": "For phase Ib only\nDetermine the maximum tolerated dose (MTD) level or minimum efficacious dose (MED) and designate the dose level for phase II.", 
                "measure": "MTD or MED Determination, Phase II Dose Level Designation", 
                "safety_issue": "Yes", 
                "time_frame": "9 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099539"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "For phase Ib and II\nNumber of participants with an objective response, which includes, a complete response, a partial response or a stable disease.", 
                "measure": "Clinical Benefit", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "For phase Ib and II\nEvaluation of the effect of ALT-803 on the peripheral ALC and WBC counts, the number and phenotype of peripheral blood T (total and subsets) and NK cells in treated patients.", 
                "measure": "Blood Cell Counts", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "For phase Ib and II\nArea under the plasma concentration-time curve from time zero to infinity (AUC) and the half-life of ALT-803.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "For phase Ib and II\nMeasures the serum levels of IL-2, IL-4, IL-6, IL-10, IFN-gamma and TNF-alpha in treated patients.", 
                "measure": "Biomarkers", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "For Phase Ib and II\nMeasures the anti-ALT-803 neutralizing effects.", 
                "measure": "Immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "All enrolled patients will be assessed every 3 months during year 1 and then every 6 months during years 2 and 3 from the start of study treatment to determine their overall survival, progression-free survival and duration of response.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Altor Bioscience Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Altor Bioscience Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}